Arcus Biosciences

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell RCUS and other ETFs, options, and stocks.

About RCUS

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of immunotherapies. It competes in the segments of the pharmaceutical, biotechnology, and other related markets that develop immunotherapies for the treatment of cancer. 

CEO
Terry J. Rosen
CEOTerry J. Rosen
Employees
627
Employees627
Headquarters
Hayward, California
HeadquartersHayward, California
Founded
2015
Founded2015
Employees
627
Employees627

RCUS Key Statistics

Market cap
2.11B
Market cap2.11B
Price-Earnings ratio
-5.78
Price-Earnings ratio-5.78
Dividend yield
Dividend yield
Average volume
2.38M
Average volume2.38M
High today
$19.74
High today$19.74
Low today
$18.64
Low today$18.64
Open price
$19.63
Open price$19.63
Volume
524.78K
Volume524.78K
52 Week high
$22.11
52 Week high$22.11
52 Week low
$6.50
52 Week low$6.50

Stock Snapshot

The current Arcus Biosciences(RCUS) stock price is $19.54, with a market capitalization of 2.11B. The stock trades at a price-to-earnings (P/E) ratio of -5.78.

As of 2025-11-05, Arcus Biosciences(RCUS) stock has fluctuated between $18.64 and $19.74. The current price stands at $19.54, placing the stock +4.8% above today's low and -1.0% off the high.

The Arcus Biosciences(RCUS)'s current trading volume is 524.78K, compared to an average daily volume of 2.38M.

During the past year, Arcus Biosciences(RCUS) stock moved between $6.50 at its lowest and $22.11 at its peak.

During the past year, Arcus Biosciences(RCUS) stock moved between $6.50 at its lowest and $22.11 at its peak.

RCUS News

The Motley Fool 3d
Arcus Biosciences President Sells $2 Million in Stock Under Trading Plan

Juan C. Jaen, the president of Arcus Biosciences (RCUS 2.33%), sold 96,859 shares in multiple open-market transactions on Tuesday and Wednesday, according to an...

Arcus Biosciences President Sells $2 Million in Stock Under Trading Plan
Simply Wall St 4d
Arcus Biosciences, Inc. Just Reported, And Analysts Assigned A US$29.60 Price Target

As you might know, Arcus Biosciences, Inc. ( ) just kicked off its latest third-quarter results with some very strong numbers. Revenues of US$26m beat estimates...

Arcus Biosciences, Inc. Just Reported, And Analysts Assigned A US$29.60 Price Target

Analyst ratings

83%

of 12 ratings
Buy
83.3%
Hold
16.7%
Sell
0%

People also own

Based on the portfolios of people who own RCUS. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.